New data from the phase III EMBRACA trial showed the PARP inhibitor talazoparib did not produce a statistically significant overall survival benefit for patients with locally advanced or metastatic HER2-negative germline BRCA­-mutated breast cancer. The secondary endpoint results from the trial were presented today at the American Association for Cancer Research (AACR) Annual Meeting by Jennifer Litton, MD, Professor of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center.

The I-SPY2 trial found that the combination of the checkpoint inhibitor durvalumab, the PARP inhibitor olaparib, and the taxane paclitaxel...

On April 22, the U.S. Food and Drug Administration (FDA) approved sacituzumab govitecan-hziy (Trodelvy) for the treatment of adult patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease.

In a phase II study reported in the Journal of Clinical Oncology, Vaz-Luis et al found that the use of a prespecified algorithm enabled the avoidance of routine peg-filgrastim prophylaxis during the paclitaxel portion of neoadjuvant or adjuvant treatment with dose-dense doxorubicin/cyclophosphamide/paclitaxel in patients with breast cancer.

Novel antibody-drug conjugates that target actionable cell-surface markers in metastatic breast cancer will soon expand the utility of the class...